# ClinicalTrials.gov record NCT02059213

> PeptideScanner retained ClinicalTrials.gov record NCT02059213 at 2026-07-30T20:22:36.939Z. Its registry update date was 2020-09-16, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct02059213-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-09-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02059213-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02059213-leuprolide-v1.json
- Content SHA-256: `da2dc8582f7863a65f46318cc21b1d8d32f696cc423dbc23f56c4d464ec36f4a`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT02059213 ([`ctg-observation-nct02059213-2020-09-16-036385976f6c`](#source-ctg-observation-nct02059213-2020-09-16-036385976f6c))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02059213 at 2026-07-30T20:22:36.939Z. Its registry update date was 2020-09-16, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02059213-2020-09-16-036385976f6c`](#source-ctg-observation-nct02059213-2020-09-16-036385976f6c))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02059213 at 2026-07-30T20:22:36.939Z. Its registry update date was 2020-09-16, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02059213-2020-09-16-036385976f6c`](#source-ctg-observation-nct02059213-2020-09-16-036385976f6c))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02059213-2020-09-16-036385976f6c`](#source-ctg-observation-nct02059213-2020-09-16-036385976f6c))

## Sources

<a id="source-ctg-observation-nct02059213-2020-09-16-036385976f6c"></a>
- **ClinicalTrials.gov record NCT02059213 · retained source version 2020-09-16:036385976f6c9d58102064b4880ae3dc1702e5bd37440d665b9de0b6bf148d3e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02059213) (`ctg-observation-nct02059213-2020-09-16-036385976f6c`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02059213." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02059213-leuprolide-v1.json SHA-256: da2dc8582f7863a65f46318cc21b1d8d32f696cc423dbc23f56c4d464ec36f4a.